---
noindex: true
sitemap: false
layout: default
title: Albuterol Sulfate
parent: Low Evidence (L5)
nav_order: 51
evidence_level: L5
indication_count: 0
last_modified_at: 2026-11-06
predicted_indications: []
---

# Albuterol Sulfate
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Albuterol Sulfate: Drug Repurposing Evaluation — Insufficient Data for Prediction
{: .text-alpha }

## One-Sentence Summary

Albuterol Sulfate is a well-known short-acting beta-2 adrenergic agonist (SABA) commonly used as a bronchodilator for conditions such as asthma and chronic obstructive pulmonary disease (COPD). However, the current Evidence Pack contains **no TxGNN-predicted new indications**, no approved indication records in the Singapore registry, and no mechanism of action data — making a full repurposing evaluation impossible at this stage. This report documents the data gaps and recommends remediation steps before any repurposing assessment can proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — prediction pipeline did not produce output |
| Singapore Market Status | Marketed (valid licences: 13 of 13) |
| Number of Registrations | 13 (valid: 13) |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN predicted indications were returned for Albuterol Sulfate in this Evidence Pack (`predicted_indications: []`). Without a prediction target, a mechanism-to-indication bridging analysis cannot be constructed.

Additionally, detailed mechanism of action data was not retrieved from DrugBank (DrugBank ID is null despite a successful query log entry). Without MOA data and a predicted disease target, the core logic of repurposing reasoning — "why would this drug's mechanism apply to a new indication?" — cannot be supported.

This section will be populated once the prediction pipeline is re-run with a valid DrugBank mapping and at least one predicted indication is returned.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for a repurposing indication.

*(No predicted indication target exists from which to derive a trial search context.)*

---

## Literature Evidence

Currently no related literature available.

*(No predicted indication target exists from which to derive a literature search context.)*

---

## Singapore Market Information

| Licence | Product | Dosage form | Status |
|------|------|------|------|
| SIN00022P | ZENMOLIN SYRUP 2 mg/5 ml | SYRUP | Valid |
| SIN02539P | VENTOLIN SOLUTION FOR INTRAVENOUS INFUSION 5 mg/5 ml | INJECTION | Valid |
| SIN02687P | VENDEROL TABLET 2 mg | TABLET | Valid |
| SIN02988P | VENTOLIN RESPIRATOR SOLUTION 0.5% w/v | SOLUTION | Valid |
| SIN05762P | VENTAMOL SYRUP 2 mg/5 ml | SYRUP | Valid |

Showing 5 of 13 HSA registrations.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Albuterol Sulfate is critically incomplete — no predicted indications, no DrugBank ID linkage, no safety data are available. There is insufficient information to evaluate any repurposing hypothesis at this time.

**To proceed, the following is needed:**

1. **Re-run TxGNN prediction pipeline** with a confirmed DrugBank ID for Albuterol Sulfate (DrugBank: DB01001 for Salbutamol) to obtain predicted indications
3. **Retrieve MOA from DrugBank API** using DB01001 to populate the mechanism of action field
4. **Download and parse the product insert (PIL/SmPC)** from HSA or EMA to populate safety warnings and contraindications
5. **Resubmit Evidence Pack** once the above data gaps (DG001, DG002) are resolved, then re-generate this report against the enriched pack
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

